Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM487HF)

• Drug Name: TUG-770 Drug Info
• Synonyms: TUG770

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 66553168
  CAS Number: CAS 1402601-82-4
  TTD Drug ID: DM487HF

Molecule-Related Drug Atlas

Drug(s) Targeting Free fatty acid receptor 1 (GPR40)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TAK-875	DMIM5AP	Type-2 diabetes	5A11	Phase 3	[3]
Fasiglifam hemihydrate	DMTGYSO	Type-2 diabetes	5A11	Phase 3	[4]
PBI-4050	DMPXK27	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[5]
P-1736	DMEYQPN	Diabetic complication	5A2Y	Phase 2	[6]
JTT-851	DMED5J6	Type-2 diabetes	5A11	Phase 2	[7]
SHR0534	DMGFTAI	Type 2 diabetes	5A11	Phase 1	[8]
LY-2881835	DM5EXJV	Type-2 diabetes	5A11	Phase 1	[7]
P11187	DMXZOI0	Type-2 diabetes	5A11	Phase 1	[7]
CPL207-280CA	DMFMGZR	Type 2 diabetes	5A11	Phase 1	[8]
LY2922470	DMGLTE2	Type 2 diabetes	5A11	Phase 1	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Free fatty acid receptor 1 (GPR40)	TTB8FUC	FFAR1_HUMAN	Agonist	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6483).
• [2] Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes. ACS Med Chem Lett. 2013 May 9;4(5):441-445.
• [3] Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab. 2015 Jul;17(7):675-81.
• [4] A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. PLoS One. 2013 Oct 10;8(10):e76280.
• [5] Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2019 Mar 18;53(3):1800663.
• [6] Discovery of p1736, a novel antidiabetic compound that improves peripheral insulin sensitivity in mice models. PLoS One. 2013 Oct 23;8(10):e77946.
• [7] Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. Front Endocrinol (Lausanne) 2014; 5: 137.
• [8] Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75.
• [9] The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). J Med Chem. 2016 Dec 22;59(24):10891-10916.